<DOC>
	<DOCNO>NCT00746655</DOCNO>
	<brief_summary>The purpose study determine feasibility toxicity combine SBRT TACE unresectable HCC evaluate Health Related Quality Life ( HRQL ) associate combined therapy .</brief_summary>
	<brief_title>SBRT + TACE Primary Hepatocellular Carcinoma</brief_title>
	<detailed_description>Patients poor surgical candidate could potentially benefit non-surgical alternative stereotactic body radiation therapy ( SBRT ) . SBRT ideal approach minimize radiation exposure normal liver maximize dose tumor . Transarterial chemoembolization ( TACE ) combine use intra-arterial chemotherapy particulate arterial embolization . This technique typically use make unresectable liver lesion amenable resection , palliation case extra-hepatic spread recurrence , symptomatic relief . The combination intraarterial chemotherapy vessel embolization make logical sense since primary secondary liver tumor derive 95 % blood supply hepatic artery , normal liver gain majority blood supply portal system . Thus , use transarterial chemoembolization possible achieve high intratumor drug concentration follow local ischemia , allow uninvolved liver spar . This study determine standard care therapy combine improve quality life patient population .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . Male female patient ≥ 18 year age 2 . A life expectancy least 12 week Karnofsky performance status least 70 ( Appendix III ) 3 . HCC confirm biopsy OR diagnose clinical radiologic criterion . All following criterion must meet biopsy require : • Known cirrhosis chronic HBV HCV infection , • Hypervascular liver mass &gt; 2 cm , either serum AFP &gt; 400 ng/ml , • AFP &gt; three time normal double value antecedent 3 month . 4 . The target lesion ( ) accurately measure least one dimension accord RECIST must combine maximum tumor volume ≤ 180 cm3 . 5 . No prior radiotherapy liver . 6 . Previous systemic chemotherapy nonradiation local therapy ( surgery , hepatic arterial therapy , chemoembolization , radiofrequency ablation , percutaneous ethanol injection cryoablation ) allow . The lesion must however show criterion progression base RECIST . Local therapy must complete least 4 week prior baseline scan . 7 . Cirrhotic status ChildPugh class A B ( Appendix I ) 8 . Patient 's lesion deem unresectable . 9 . Patient 's tumor burden medical comorbidities disqualify transplant OR patient qualifies transplant refuse operation OR patient plan TACE bridge transplant operation . 10 . Platelet count ≥ 60 x 109/L , Hemoglobin ≥ 8.5 g/dL , WBC ≥ 2000/μL International normalize ratio ( INR ) ≤ 1.5 PT/PTT within normal limit . Patients therapeutically anticoagulated agent Coumadin heparin allow participate provide prior evidence underlie abnormality parameter exist . 11 . Other baseline lab must meet following criterion : total bilirubin &lt; 3mg/dl , albumin &gt; 2.5mg/dl , liver enzymes less three time upper limit normal . Creatinine must also &lt; 1.8mg/dl creatinine clearance &gt; 50ml/min . 12 . Must aware neoplastic nature his/her disease willingly provide write , informed consent inform procedure follow , nature therapy , alternative , potential benefit , sideeffects , risk discomfort . 1 . Renal failure require hemo peritoneal dialysis 2 . Uncontrolled intercurrent illness ( except Hepatitis ) include , limited ongoing active infection ( &gt; grade 2 National Cancer Institute [ NCI ] Common Terminology Criteria Adverse Events [ CTCAE ] version 3.0 ) , congestive heart failure ( &gt; New York Heart Association ( NYHA ) class 2 ) , active coronary artery disease ( CAD ) , cardiac arrhythmia require antiarrhythmic therapy beta blocker digoxin ) , uncontrolled hypertension condition could jeopardize safety patient his/her compliance study . Myocardial infarction 6 month prior study entry permit . 3 . A history variceal bleed varix eradicate decompressed shunt placement . 4 . History active connective tissue disorder . 5 . Substance abuse , medical , psychological social condition may interfere patient 's participation study evaluation study result 6 . Pregnant breastfeeding patient exclude study abdominal radiation therapy potential teratogenic and/or abortifacient effect . 7 . Total portal vein occlusion . 8 . Extensive liver tumor burden , define 75 % liver . 9 . Previous current malignancy histology within last 5 year , exception cervical carcinoma situ adequately treat basal cell squamous cell carcinoma skin . 10 . Patients uncontrolled distant disease exclude protocol . Those controlled systemic disease still eligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Hepatocellular</keyword>
</DOC>